Medicare Expands GLP-1 Coverage to Weight Loss at $50 Copay, Anchoring a New Health-Economy Shift
Medicare’s one-year Bridge Program now covers GLP-1 weight-loss medications (Foundayo, Wegovy, or Zepbound) for a $50 copay, extending access beyond diabetics to those with BMI 35+ or 27+ with conditions. The move could be a watershed for obesity treatment and trigger broader economic and policy shifts as demand and costs rise.